The first Australian participant has been enrolled in the global VIGOR trial, sponsored by ONJCRI in collaboration with COGNO in Australia.
The trial will investigate vorasidenib maintenance treatment in people with IDH-mutant grade 2/3 astrocytoma.
@onjcri.org.au